查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1871161

mRNA療法市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

mRNA Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球 mRNA 療法市場價值為 155 億美元，預計到 2034 年將以 14.4% 的複合年成長率成長至 589 億美元。

mRNA療法市場 - IMG1

信使RNA (mRNA) 平台的技術突破以及醫療專業人員和監管機構對其臨床潛力的日益成長的信心，推動了mRNA療法的快速成長。近年來，mRNA已被證明能夠實現可擴展、靈活且高效的藥物研發流程。脂質奈米顆粒 (LNP) 遞送系統的重大進步，透過解決分解和免疫反應方面的挑戰，進一步提高了mRNA分子的精準性、安全性和生物利用度。 mRNA技術最初專注於預防傳染病，如今正擴大應用於治療慢性複雜疾病，包括心血管疾病、自體免疫疾病和罕見遺傳性疾病。其獨特的編碼體內特定蛋白質的能力，使得標靶和個人化治療成為可能，從而重塑了現代醫學的未來。這種變革性的方法使mRNA療法成為生物技術領域成長最快的領域之一，加速了全球製藥和生物製藥產業的創新進程。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 155億美元
預測值 589億美元
複合年成長率 14.4%

2024年，疫苗領域佔據81.9%的市場佔有率，預計到2034年將達到477億美元，2025年至2034年間的複合年成長率（CAGR）為14.3%。無細胞合成技術的高效性推動了該領域的擴張，與傳統疫苗相比，該技術縮短了生產時間。 mRNA疫苗能夠快速調整配方以應對新出現的變異株或病原體，使其具有高度的通用性。模組化生產裝置和脂質奈米顆粒系統的持續創新進一步提升了產品的穩定性、可擴展性和成本效益，從而增強了其全球可及性。

到2034年，mRNA治療領域將以14.6%的複合年成長率成長，這主要得益於mRNA技術在癌症、自體免疫疾病和遺傳性疾病治療中日益廣泛的應用。與傳統生物製劑不同，基於mRNA的藥物無需改變患者的DNA即可暫時表達治療性蛋白，從而提高了安全性和靈活性。研究和臨床試驗資金的增加拓寬了mRNA療法的研發管線，吸引了許多渴望利用這一前景廣闊的平台的製藥和生物技術公司。

2024年，北美mRNA療法市場佔42.4%的佔有率。該地區的領先地位歸功於其先進的研發能力、強大的生物技術基礎設施以及眾多擁有龐大生產和臨床試驗能力的全球主要企業。北美完善的醫療保健生態系統，包括領先的醫院、診所和學術研究中心，為mRNA產品的生產和應用提供了強力的支持。對個人化醫療的大力投入、先進的冷鏈物流以及廣泛的監管支持，進一步鞏固了該地區的市場主導地位和持續成長。

全球mRNA療法市場的主要參與者包括Moderna、輝瑞、BioNTech、葛蘭素史克、CureVac、阿斯特捷利康、Translate Bio、賽諾菲、Arcturus Therapeutics、Ethris、Chimeron Bio、Tiba Biotech、VaxEquity、Immorna Biotech和StemiRNA Therapeutics。這些企業正致力於擴大產能、推動遞送技術並加強全球供應鏈。製藥公司和生物技術公司之間的策略合作正在加速研究成果轉化並擴大臨床試驗的發展。各公司正大力投資下一代脂質奈米顆粒系統，以提高遞送精度並降低免疫原性。產品線多角化，拓展至腫瘤、心血管和罕見疾病領域，也是實現長期成長的核心策略。許多企業正在採用模組化和自動化生產流程，以降低成本並提高規模化生產能力。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

  • 產業生態系分析
    • 供應商格局
    • 每個階段的價值增加
    • 影響價值鏈的因素
  • 產業影響因素
    • 成長促進因素
      • 配送技術的進步
      • 拓展疫苗以外的應用
      • 對生物技術研發的投資不斷成長
      • 更快、可擴展的製造
    • 產業陷阱與挑戰
      • 免疫原性和安全性問題
      • 製造和可擴展性問題
    • 市場機遇
      • 拓展至蛋白質替代療法領域
      • 與人工智慧和基因組學的整合
  • 成長潛力分析
  • 監管環境
    • 北美洲
    • 歐洲
    • 亞太地區
  • 技術格局
    • 當前技術趨勢
    • 新興技術
  • 未來市場趨勢
  • 定價分析
  • 臨床試驗分析
  • 波特的分析
  • PESTEL 分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估算與預測：依產品分類，2021-2034年

  • 主要趨勢
  • 藥物
    • 治療性mRNA蛋白
    • 其他基於mRNA的藥物
  • 疫苗
    • 自擴增mRNA疫苗
    • 傳統非擴增型mRNA疫苗

第6章：市場估算與預測：依應用領域分類，2021-2034年

  • 主要趨勢
  • 傳染病
  • 腫瘤學
  • 罕見遺傳疾病
  • 呼吸系統疾病
  • 其他應用

第7章：市場估算與預測：依類型分類，2021-2034年

  • 主要趨勢
  • 預防
  • 治療

第8章：市場估算與預測：依最終用途分類，2021-2034年

  • 主要趨勢
  • 醫院和診所
  • 製藥公司
  • 研究機構
  • 其他最終用途

第9章：市場估計與預測：依地區分類，2021-2034年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • CureVac
  • BioNtech
  • Ethris
  • Moderna
  • Pfizer
  • GlaxoSmithKline
  • Translate Bio
  • Arcturus Therapeutics
  • Sanofi
  • AstraZeneca
  • Chimeron Bio
  • Tiba Biotech
  • VaxEquity
  • StemiRNA Therapeutics
  • Immorna Biotech
簡介目錄
Product Code: 15010

The Global mRNA Therapeutics Market was valued at USD 15.5 Billion in 2024 and is estimated to grow at a CAGR of 14.4% to reach USD 58.9 Billion by 2034.

mRNA Therapeutics Market - IMG1

The surge in growth is driven by technological breakthroughs in messenger RNA (mRNA) platforms and the increasing confidence among healthcare professionals and regulators in their clinical potential. Recent years have proven mRNA's ability to enable scalable, flexible, and highly efficient drug development processes. Major advancements in lipid nanoparticle (LNP) delivery systems have further enhanced the precision, safety, and bioavailability of mRNA molecules by addressing degradation and immune response challenges. mRNA technology, once focused on preventing infectious diseases, is now being increasingly applied to treat chronic and complex conditions, including cardiovascular, autoimmune, and rare genetic disorders. Its unique capacity to encode specific proteins inside the body allows for targeted and personalized therapies, reshaping the future of modern medicine. This transformative approach positions mRNA therapeutics as one of the fastest-growing domains in biotechnology, accelerating innovation pipelines across pharmaceutical and biopharmaceutical industries worldwide.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$15.5 Billion
Forecast Value$58.9 Billion
CAGR14.4%

The vaccines segment held 81.9% share in 2024 and is projected to reach USD 47.7 Billion by 2034, registering a CAGR of 14.3% during 2025-2034. The segment's expansion is supported by the efficiency of cell-free synthesis, which shortens production time compared to traditional vaccines. The ability to rapidly adapt formulations for emerging variants or pathogens makes mRNA vaccines highly versatile. Continuous innovations in modular production setups and lipid nanoparticle systems are further enhancing product stability, scalability, and cost-effectiveness, strengthening their global accessibility.

The therapeutics segment will grow at a CAGR of 14.6% through 2034, driven by mRNA technology's expanding role in the treatment of cancer, autoimmune diseases, and genetic disorders. Unlike conventional biologics, mRNA-based drugs enable temporary expression of therapeutic proteins without modifying the patient's DNA, offering improved safety and flexibility. Increased funding in research and clinical trials has widened the development pipeline for mRNA therapeutics, attracting pharmaceutical and biotech companies eager to capitalize on this promising platform.

North America mRNA Therapeutics Market held a 42.4% share in 2024. The region's leadership is attributed to its advanced R&D capabilities, strong biotech infrastructure, and presence of major global players with extensive manufacturing and clinical trial capacities. North America's robust healthcare ecosystem, which includes leading hospitals, clinics, and academic research centers, supports both the production and administration of mRNA-based products. High investment in personalized medicine, advanced logistics for cold chain maintenance, and widespread regulatory support have further reinforced the region's dominant position and continuous market growth.

Prominent companies active in the Global mRNA Therapeutics Market include Moderna, Pfizer, BioNTech, GlaxoSmithKline, CureVac, AstraZeneca, Translate Bio, Sanofi, Arcturus Therapeutics, Ethris, Chimeron Bio, Tiba Biotech, VaxEquity, Immorna Biotech, and StemiRNA Therapeutics. Key players in the mRNA Therapeutics Market are focusing on expanding production capacity, advancing delivery technologies, and strengthening global supply chains. Strategic partnerships between pharmaceutical and biotech firms are enabling faster research translation and broader clinical trial execution. Companies are heavily investing in next-generation lipid nanoparticle systems to improve delivery precision and reduce immunogenicity. Diversification of product pipelines toward oncology, cardiovascular, and rare diseases is also a central strategy for long-term growth. Many players are adopting modular and automated manufacturing processes to lower costs and enhance scalability.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Application trends
    • 2.2.4 Type trends
    • 2.2.5 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factors affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Advancements in delivery technologies
      • 3.2.1.2 Expanding applications beyond vaccines
      • 3.2.1.3 Growing investment in biotechnology research and development
      • 3.2.1.4 Faster and scalable manufacturing
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Immunogenicity and safety concerns
      • 3.2.2.2 Manufacturing and scalability issues
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion into protein replacement therapies
      • 3.2.3.2 Integration with AI and genomics
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Future market trends
  • 3.7 Pricing analysis
  • 3.8 Clinical trial analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Bn)

  • 5.1 Key trends
  • 5.2 Drugs
    • 5.2.1 Therapeutic mRNA proteins
    • 5.2.2 Other mRNA-based drugs
  • 5.3 Vaccines
    • 5.3.1 Self-amplifying mRNA vaccines
    • 5.3.2 Conventional non-amplifying mRNA vaccines

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Bn)

  • 6.1 Key trends
  • 6.2 Infectious disease
  • 6.3 Oncology
  • 6.4 Rare genetic disorders
  • 6.5 Respiratory disease
  • 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Bn)

  • 7.1 Key trends
  • 7.2 Prophylactic
  • 7.3 Therapeutic

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Bn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Pharmaceutical companies
  • 8.4 Research institutes
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Bn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 CureVac
  • 10.2 BioNtech
  • 10.3 Ethris
  • 10.4 Moderna
  • 10.5 Pfizer
  • 10.6 GlaxoSmithKline
  • 10.7 Translate Bio
  • 10.8 Arcturus Therapeutics
  • 10.9 Sanofi
  • 10.10 AstraZeneca
  • 10.11 Chimeron Bio
  • 10.12 Tiba Biotech
  • 10.13 VaxEquity
  • 10.14 StemiRNA Therapeutics
  • 10.15 Immorna Biotech